Abstract
Aim: To evaluate the advantages of nanomaterial methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) encapsulated doxorubicin (D/DOX) and paclitaxel (T/TAX; mPEG-PLGA-DT) over free form of DOX and TAX (DOX/TAX). Materials & methods: Metabonomics was conducted to characterize the systemic metabolic response of allograft breast cancer model mice to mPEG-PLGA-DT and DOX/TAX treatments. Results: Breast tumor growth induced metabolic reprogram in serum and multiple organs. DOX/TAX treatment could ameliorate the elevated energy and nucleotides demands in some organs while mPEG-PLGA-DT treatment showed outstanding therapeutic outcomes in restoring the metabolic phenotypes of serum and kidney from tumor-bearing mice to the healthy state. Conclusion: This investigation proved the biological advantages of mPEG-PLGA-DT over DOX/TAX in molecular level through the comparison between their metabolic responses in vivo.
Original language | English |
---|---|
Pages (from-to) | 913-928 |
Number of pages | 16 |
Journal | Nanomedicine |
Volume | 13 |
Issue number | 8 |
DOIs | |
Publication status | Published - Apr 2018 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2018 Future Medicine Ltd.
ASJC Scopus Subject Areas
- Bioengineering
- Medicine (miscellaneous)
- Biomedical Engineering
- General Materials Science
- Development
Keywords
- Anticancer drugs
- Biomedical applications
- Metabonomics
- NMR
- Nuclear magnetic resonance
- Polymer nanoparticles